Methods for treating inflammatory bowel disease

• US 8,536,140 B2
• Filed: 12/13/2010
• Issued: 09/17/2013
• Est. Priority Date: 03/12/2004
• Status: Expired due to Fees

• Current Assignee: MTI Meta Tech, Inc.
• Original Assignee: MTI Meta Tech, Inc.
• Inventors: Clandinin, Michael Thomas, Park, Eek J.
• Primary Examiner(s): OLSON, ERIC
• Application Number:
  US12/966,070
• Publication Number:
  US 20110144041A1
• Time in Patent Office: 1,009 Days
• Field of Search: None
• US Class Current: 514/25
• CPC Class Codes: A61K 31/7032 attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
• CPC Class Codes: A61K 31/739 Lipopolysaccharides
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: C07H 15/10 containing unsaturated carbon-to-carbon bonds

Abstract

A method is described for treating inflammatory bowel disease in a subject in need thereof. The method comprises administering a formulation comprising at least one ganglioside to the subject, wherein the formulation comprises at least about 50% GD3 by weight of total ganglioside content.

Claims

1. A method for treating inflammatory bowel disease in a subject ineed thereof, the method comprising administering a formulation comprising at least one ganglioside to the subject, wherein the at least one ganglioside comprises at least about 80% GD3 by weight of total ganglioside content.

4. The method of claim 1, wherein the formulation is administered to provide from about 1 mg/day to about 10 g/day of ganglioside.

5. The method of claim 1, wherein the formulation is administered to provide from about 5 mg/day to about 500 mg/day of ganglioside.

6. The method of claim 1, wherein lipid components in microdomains are altered by a reduction in platelet activating factor (PAF), a reduction in the ratio of cholesterol to sphingolipid, or a reduction in total diglyceride in the microdomains.

7. The method according to claim 1, wherein the formulation additionally comprises a ganglioside selected from the group consisting of:

GM1, GM2, GM3, and GD1b.

8. The method according to claim 7, wherein the formulation comprises about 80% GD3 and about 5% GM3 by weight based on total ganglioside content.

9. The method of claim 1, wherein administering comprises oral consumption.

10. The method of claim 1, wherein the formulation comprises a ganglioside supplemented liquid or food.

11. The method of claim 10 wherein the formulation is a supplemented liquid comprising about 0.01 to about 1000 ppm ganglioside.

12. The method of claim 10 wherein the formulation comprises milk having a fat fraction of from about 1 to about 4% by weight, wherein the fat fraction comprises from about 0.1% to about 2.0% by weight ganglioside.

13. The method of claim 1 wherein inflammatory bowel disease comprises Crohn'"'"'s disease or ulcerative colitis.

2. A method for treating inflammatory bowel disease in a subject ineed thereof, the method comprising administering a formulation comprising at least one ganglioside to the subject, wherein the formulation comprises at least about 50% GD3 by weight of total ganglioside content and about 10% GD1b by weight of total ganglioside content.

14. The method of claim 2, wherein the formulation is administered to provide from about 1 mg/day to about 10 g/day of ganglioside.

15. The method of claim 2, wherein the formulation is administered to provide from about 5 mg/day to about 500 mg/day of ganglioside.

16. The method of claim 2, wherein lipid components in microdomains are altered by a reduction in platelet activating factor (PAP), a reduction in the ratio of cholesterol to sphingolipid, or a reduction in total diglyceride in the microdomains.

17. The method of claim 2, wherein administering comprises oral consumption.

18. The method of claim 2, wherein the formulation comprises a ganglioside supplemented liquid or food.

19. The method of claim 18, wherein the formulation is a supplemented liquid comprising about 0.01 to about 1000 ppm ganglioside.

20. The method of claim 18 wherein the formulation comprises milk having a fat fraction of from about 1 to about 4% by weight, wherein the fat fraction comprises from about 0.1% to about 2.0% by weight ganglioside.

21. The method of claim 2 wherein inflammatory bowel disease comprises Crohn'"'"'s disease or ulcerative colitis.

3. A method for treating inflammatory bowel disease in a subject ineed thereof, the method comprising administering a formulation comprising at least one ganglioside to the subject, wherein the formulation comprises at least about 50% GD3 by weight of total ganglioside content and about 5% GM3 by weight of total ganglioside content.

22. The method of claim 3, wherein the formulation is administered to provide from about 1 mg/day to about 10 g/day of ganglioside.

23. The method of claim 3, wherein the formulation is administered to provide from about 5 mg/day to about 500 mg/day of ganglioside.

24. The method of claim 3, wherein lipid components in microdomains are altered by a reduction in platelet activating factor (PAF), a reduction in the ratio of cholesterol to sphingolipid, or a reduction in total diglyceride in the microdomains.

25. The method of claim 3, wherein administering comprises oral consumption.

26. The method of claim 3, wherein the formulation comprises a ganglioside supplemented liquid or food.

27. The method of claim 26, wherein the formulation is a supplemented liquid comprising about 0.01 to about 1000 ppm ganglioside.

28. The method of claim 26 wherein the formulation comprises milk having a fat fraction of from about 1 to about 4% by weight, wherein the fat fraction comprises from about 0.1% to about 2.0% by weight ganglioside.

29. The method of claim 3 wherein inflammatory bowel disease comprises Crohn'"'"'s disease or ulcerative colitis.